Prevalence and incidence of psychotic disorders in 22q11.2 deletion syndrome: a meta-analysis

References

• Armando, M., Girardi, P., Vicari, S., Menghini, D., Digilio, M. C., Pontillo, M., Saba, R., Mazzone, L., Lin, A., Klier, C. M., Schäfer, M. R., & Amminger, G. P. (2012). Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning. Schizophrenia Research, 139(1-3), 151–156. https://doi.org/10.1016/j.schres.2012.04.020
   PubMed Web of Science ®Google Scholar
• Bassett, A. S., Chow, E. W. C., AbdelMalik, P., Gheorghiu, M., Husted, J., & Weksberg, R. (2003). The schizophrenia phenotype in 22q11 deletion syndrome. The American Journal of Psychiatry, 160(9), 1580–1586. https://doi.org/10.1176/appi.ajp.160.9.1580
   PubMed Web of Science ®Google Scholar
• Bassett, A. S., Chow, E. W. C., Husted, J., Weksberg, R., Caluseriu, O., Webb, G. D., & Gatzoulis, M. A. (2005). Clinical features of 78 adults with 22q11 deletion syndrome. American Journal of Medical Genetics. Part A, 138(4), 307–313.
   PubMedGoogle Scholar
• Bassett, A. S., Lowther, C., Merico, D., Costain, G., Chow, E. W. C., van Amelsvoort, T., McDonald-McGinn, D., Gur, R. E., Swillen, A., Van den Bree, M., Murphy, K., Gothelf, D., Bearden, C. E., Eliez, S., Kates, W., Philip, N., Sashi, V., Campbell, L., Vorstman, J., … Marshall, C. R, International 22q11.2DS Brain and Behavior Consortium (2017). Rare genome-wide copy number variation and expression of schizophrenia in 22q11.2 deletion syndrome. The American Journal of Psychiatry, 174(11), 1054–1063. https://doi.org/10.1176/appi.ajp.2017.16121417
   PubMed Web of Science ®Google Scholar
• Bertran, M., Tagle, F. P., & Irarrazaval, M. (2018). Psychiatric manifestations of 22q11.2 deletion syndrome: a literature review. Neurologia (Barcelona, Spain), 33(2), 121–128. https://doi.org/10.1016/j.nrleng.2015.07.014
   PubMed Web of Science ®Google Scholar
• Biswas, A. B., & Furniss, F. (2016). Cognitive phenotype and psychiatric disorder in 22q11.2 deletion syndrome: A review. Research in Developmental Disabilities, 53-54, 242–257. https://doi.org/10.1016/j.ridd.2016.02.010
   PubMed Web of Science ®Google Scholar
• Bretelle, F., Beyer, L., Pellissier, M. C., Missirian, C., Sigaudy, S., Gamerre, M., D'Ercole, C., & Philip, N. (2010). Prenatal and postnatal diagnosis of 22q11.2 deletion syndrome. European Journal of Medical Genetics, 53(6), 367–370. https://doi.org/10.1016/j.ejmg.2010.07.008
   PubMed Web of Science ®Google Scholar
• Butcher, N. J., Kiehl, T.-R., Hazrati, L.-N., Chow, E. W. C., Rogaeva, E., Lang, A. E., & Bassett, A. S. (2013). Association between early-onset parkinson disease and 22q11.2 deletion syndrome identification of a novel genetic form of parkinson disease and its clinical implications. JAMA Neurology, 70(11), 1359–1366. https://doi.org/10.1001/jamaneurol.2013.3646
   PubMed Web of Science ®Google Scholar
• Catalan, A., Salazar de Pablo, G., Aymerich, C., Damiani, S., Sordi, V., Radua, J., Oliver, D., McGuire, P., Giuliano, A. J., Stone, W. S., & Fusar-Poli, P. (2021). Neurocognitive functioning in individuals at clinical high risk for psychosis: a systematic review and meta-analysis. JAMA Psychiatry, 78(8), 859. https://doi.org/10.1001/jamapsychiatry.2021.1290
   PubMed Web of Science ®Google Scholar
• Catalan, A., Salazar de Pablo, G., Vaquerizo Serrano, J., Mosillo, P., Baldwin, H., Fernández‐Rivas, A., Moreno, C., Arango, C., Correll, C. U., Bonoldi, I., & Fusar‐Poli, P. (2021). Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention. Journal of Child Psychology and Psychiatry, 62(5), 657–673. https://doi.org/10.1111/jcpp.13322
   PubMed Web of Science ®Google Scholar
• Cooper, S.-A., Smiley, E., Morrison, J., Williamson, A., & Allan, L. (2007). Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. The British Journal of Psychiatry : The Journal of Mental Science, 190, 27–35. https://doi.org/10.1192/bjp.bp.106.022483
   PubMed Web of Science ®Google Scholar
• Davies, R. W., Fiksinski, A. M., Breetvelt, E. J., Williams, N. M., Hooper, S. R., Monfeuga, T., Bassett, A. S., Owen, M. J., Gur, R. E., Morrow, B. E., McDonald-McGinn, D. M., Swillen, A., Chow, E. W. C., van den Bree, M., Emanuel, B. S., Vermeesch, J. R., van Amelsvoort, T., Arango, C., Armando, M., … Vorstman, J. A. S., International 22q11.2 Brain and Behavior Consortium. (2020). Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nature Medicine, 26(12), 1912–1918. https://doi.org/10.1038/s41591-020-1103-1
   PubMed Web of Science ®Google Scholar
• Delio, M., Guo, T., McDonald-McGinn, D. M., Zackai, E., Herman, S., Kaminetzky, M., Higgins, A. M., Coleman, K., Chow, C., Jalbrzikowski, M., Jarlbrzkowski, M., Bearden, C. E., Bailey, A., Vangkilde, A., Olsen, L., Olesen, C., Skovby, F., Werge, T. M., Templin, L., … Morrow, B. E. (2013). Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and digeorge syndromes. American Journal of Human Genetics, 92(3), 439–447. https://doi.org/10.1016/j.ajhg.2013.01.018
   PubMed Web of Science ®Google Scholar
• DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. https://doi.org/10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Driscoll, D. A. (2001). Prenatal diagnosis of the 22q11.2 deletion syndrome. Genetics in Medicine : official Journal of the American College of Medical Genetics, 3(1), 14–18. https://doi.org/10.1097/00125817-200101000-00004
   PubMed Web of Science ®Google Scholar
• Estradé, A., Salazar de Pablo, G., Zanotti, A., Wood, S., Fisher, H. L., & Fusar-Poli, P. (2022). Public health primary prevention implemented by clinical high-risk services for psychosis. Translational Psychiatry, 12(1), 43. https://doi.org/10.1038/s41398-022-01805-4
   PubMed Web of Science ®Google Scholar
• Fiksinski, A. M. (2021). A normative chart for cognitive development in a genetically selected population. Neuropsychopharmacology, 47(7):1379–1386.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., Bechdolf, A., Taylor, M. J., Bonoldi, I., Carpenter, W. T., Yung, A. R., & McGuire, P. (2013). At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophrenia Bulletin, 39(4), 923–932. https://doi.org/10.1093/schbul/sbs060
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., Cappucciati, M., Bonoldi, I., Hui, L. M. C., Rutigliano, G., Stahl, D. R., Borgwardt, S., Politi, P., Mishara, A. L., Lawrie, S. M., Carpenter, W. T., & McGuire, P. K. (2016). Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry, 73(3), 211–220. https://doi.org/10.1001/jamapsychiatry.2015.2313
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., Cappucciati, M., De Micheli, A., Rutigliano, G., Bonoldi, I., Tognin, S., Ramella-Cravaro, V., Castagnini, A., & McGuire, P. (2017). Diagnostic and prognostic significance of brief limited intermittent Psychotic Symptoms (BLIPS) in individuals at ultra high risk. Schizophrenia Bulletin, 43(1), 48–56. https://doi.org/10.1093/schbul/sbw151
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., De Micheli, A., Chalambrides, M., Singh, A., Augusto, C., & McGuire, P. (2019). Unmet needs for treatment in 102 individuals with brief and limited intermittent psychotic symptoms (BLIPS): implications for current clinical recommendations. Epidemiology and Psychiatric Sciences, 29, e67.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., Salazar de Pablo, G., Correll, C. U., Meyer-Lindenberg, A., Millan, M. J., Borgwardt, S., Galderisi, S., Bechdolf, A., Pfennig, A., Kessing, L. V., van Amelsvoort, T., Nieman, D. H., Domschke, K., Krebs, M.-O., Koutsouleris, N., McGuire, P., Do, K. Q., & Arango, C. (2020). Prevention of psychosis: advances in detection, prognosis, and intervention. JAMA Psychiatry, 77(7), 755–765. https://doi.org/10.1001/jamapsychiatry.2019.4779
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., Salazar de Pablo, G., Rajkumar, R. P., López-Díaz, Á., Malhotra, S., Heckers, S., Lawrie, S. M., & Pillmann, F. (2022). Diagnosis, prognosis, and treatment of brief psychotic episodes: a review and research agenda. The Lancet. Psychiatry, 9(1), 72–83. https://doi.org/10.1016/S2215-0366(21)00121-8
   PubMed Web of Science ®Google Scholar
• Gerdes, M., Solot, C., Wang, P. P., Moss, E., LaRossa, D., Randall, P., Goldmuntz, E., Clark, B. J., Driscoll, D. A., Jawad, A., Emanuel, B. S., McDonald-McGinn, D. M., Batshaw, M. L., & Zackai, E. H. (1999). Cognitive and behavior profile of preschool children with chromosome 22q11.2 deletion. American Journal of Medical Genetics, 85(2), 127–133. https://doi.org/10.1002/(SICI)1096-8628(19990716)85:2 < 127::AID-AJMG6 > 3.0.CO;2-F
   PubMed Web of Science ®Google Scholar
• Gothelf, D., Schneider, M., Green, T., Debbané, M., Frisch, A., Glaser, B., Zilkha, H., Schaer, M., Weizman, A., & Eliez, S. (2013). Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study. Journal of the American Academy of Child and Adolescent Psychiatry, 52(11), 1192–1203.e3. https://doi.org/10.1016/j.jaac.2013.08.008
   PubMed Web of Science ®Google Scholar
• Guipponi, M., Santoni, F., Schneider, M., Gehrig, C., Bustillo, X. B., Kates, W. R., Morrow, B., Armando, M., Vicari, S., Sloan-Béna, F., Gagnebin, M., Shashi, V., Hooper, S. R., Eliez, S., & Antonarakis, S. E. (2017). No evidence for the presence of genetic variants predisposing to psychotic disorders on the non-deleted 22q11.2 allele of VCFS patients. Translational Psychiatry, 7(2), e1039–e1039. https://doi.org/10.1038/tp.2016.258
   PubMedGoogle Scholar
• Hacıhamdioğlu, B., Berberoğlu, M., Şıklar, Z., Doğu, F., Bilir, P., Savaş Erdeve, Ş., İkincioğulları, A., & Öçal, G. (2011). Case report: two patients with partial DiGeorge syndrome presenting with attention disorder and learning difficulties. Journal of Clinical Research in Pediatric Endocrinology, 3(2), 95–97. https://doi.org/10.4274/jcrpe.v3i2.19
   PubMed Web of Science ®Google Scholar
• Jhawar, N., Brown, M. J., Cutler-Landsman, D., Kates, W. R., Angkustsiri, K., & Antshel, K. M. (2021). Longitudinal psychiatric and developmental outcomes in 22q11.2 deletion syndrome: A systematic review. Journal of Developmental and Behavioral Pediatrics : JDBP, 42(5), 415–427.
   PubMed Web of Science ®Google Scholar
• Jongsma, H. E., Turner, C., Kirkbride, J. B., & Jones, P. B. (2019). International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. The Lancet. Public Health, 4(5), e229–e244. https://doi.org/10.1016/S2468-2667(19)30056-8
   PubMed Web of Science ®Google Scholar
• Lipsey, M. W., & Wilson, D. B. (2001). Practical meta-analysis. Sage Publications, Inc.
   Google Scholar
• Marshall, C. R., Howrigan, D. P., Merico, D., Thiruvahindrapuram, B., Wu, W., Greer, D. S., Antaki, D., Shetty, A., Holmans, P. A., Pinto, D., Gujral, M., Brandler, W. M., Malhotra, D., Wang, Z., Fajarado, K. V. F., Maile, M. S., Ripke, S., Agartz, I., Albus, M., … Sebat, J., CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium. (2017). Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 49(1), 27–35. https://doi.org/10.1038/ng.3725
   PubMed Web of Science ®Google Scholar
• McDonald-McGinn, D. M., Kirschner, R., Goldmuntz, E., Sullivan, K., Eicher, P., Gerdes, M., Moss, E., Solot, C., Wang, P., Jacobs, I., Handler, S., Knightly, C., Heher, K., Wilson, M., Ming, J. E., Grace, K., Driscoll, D., Pasquariello, P., Randall, P., … Zackai, E. H. (1999). The Philadelphia story: The 22q11.2 deletion: Report on 250 patients. Genetic Counseling (Geneva, Switzerland), 10(1), 11–24.
   PubMedGoogle Scholar
• McDonald-McGinn, D. M., Sullivan, K. E., Marino, B., Philip, N., Swillen, A., Vorstman, J. A. S., Zackai, E. H., Emanuel, B. S., Vermeesch, J. R., Morrow, B. E., Scambler, P. J., & Bassett, A. S. (2015). 22q11.2 deletion syndrome. Nature Reviews Disease Primers, 1(1), 15071. https://doi.org/10.1038/nrdp.2015.71
   PubMedGoogle Scholar
• McGlashan, T. H., &  W. B., Wood, S. J. (2010). The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up. Oxford University Press.
   Google Scholar
• McLean-Tooke, A., Spickett, G. P., & Gennery, A. R. (2007). Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scandinavian Journal of Immunology, 66(1), 1–7. https://doi.org/10.1111/j.1365-3083.2007.01949.x
   PubMed Web of Science ®Google Scholar
• Minichino, A., Rutigliano, G., Merlino, S., Davies, C., Oliver, D., De Micheli, A., Patel, R., McGuire, P., & Fusar-Poli, P. (2019). Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. European Psychiatry : The Journal of the Association of European Psychiatrists, 57, 26–32. https://doi.org/10.1016/j.eurpsy.2018.12.006
   PubMed Web of Science ®Google Scholar
• Modesti, P. A., Reboldi, G., Cappuccio, F. P., Agyemang, C., Remuzzi, G., Rapi, S., Perruolo, E., & Parati, G, ESH Working Group on CV Risk in Low Resource Settings (2016). Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. PLoS One. 11(1), e0147601. https://doi.org/10.1371/journal.pone.0147601
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G, PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Monks, S., Niarchou, M., Davies, A. R., Walters, J. T. R., Williams, N., Owen, M. J., van den Bree, M. B. M., & Murphy, K. C. (2014). Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome. Schizophrenia Research, 153(1-3), 231–236. https://doi.org/10.1016/j.schres.2014.01.020
   PubMed Web of Science ®Google Scholar
• Morrow, B. E., McDonald-McGinn, D. M., Emanuel, B. S., Vermeesch, J. R., & Scambler, P. J. (2018). Molecular genetics of 22q11.2 deletion syndrome. American Journal of Medical Genetics. Part A, 176(10), 2070–2081. https://doi.org/10.1002/ajmg.a.40504
   PubMed Web of Science ®Google Scholar
• Napoletano, F., Andlauer, O., Murguia-Asensio, S., Eranti, S. V., Akyuz, E., Estradé, A., Buhagiar, J., David, C., Fusar-Poli, P., & Gupta, S. (2022). Establishing a business case for setting up early detection services for preventing psychosis. BJPsych Bulletin, 1–10. https://doi.org/10.1192/bjb.2022.7
   Web of Science ®Google Scholar
• Niarchou, M., Chawner, S. J., Fiksinski, A., Vorstman, J. A., Maeder, J., Schneider, M., Eliez, S., Armando, M., Pontillo, M., Vicari, S., McDonald-McGinn, D. M., Emanuel, B. S., Zackai, E. H., Bearden, C. E., Shashi, V., Hooper, S. R., Owen, M. J., Gur, R. E., Wray, N. R., van den Bree, M. B., & Thapar, A. (2019). Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome. Schizophrenia Research, 204, 320–325. https://doi.org/10.1016/j.schres.2018.07.044
   PubMed Web of Science ®Google Scholar
• Padula, M. C., Schaer, M., Armando, M., Sandini, C., Zöller, D., Scariati, E., Schneider, M., & Eliez, S. (2018). Cortical morphology development in patients with 22q11.2 deletion syndrome at ultra-high risk of psychosis. Psychological Medicine, 48(14), 2375–2383. https://doi.org/10.1017/S0033291717003920
   PubMed Web of Science ®Google Scholar
• Park, I.-S., Ko, J.-K., Kim, Y.-H., Yoo, H.-W., Seo, E.-J., Choi, J.-Y., Gil, H.-Y., & Kim, S.-J. (2007). Cardiovascular anomalies in patients with chromosome 22q11.2 deletion: A Korean multicenter study. International Journal of Cardiology, 114(2), 230–235. https://doi.org/10.1016/j.ijcard.2005.12.029
   PubMed Web of Science ®Google Scholar
• Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppä, T., Härkänen, T., Koskinen, S., & Lönnqvist, J. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry, 64(1), 19–28. https://doi.org/10.1001/archpsyc.64.1.19
   PubMed Web of Science ®Google Scholar
• Salazar de Pablo, G., Besana, F., Arienti, V., Catalan, A., Vaquerizo-Serrano, J., Cabras, A., Pereira, J., Soardo, L., Coronelli, F., Kaur, S., da Silva, J., Oliver, D., Petros, N., Moreno, C., Gonzalez-Pinto, A., Díaz-Caneja, C. M., Shin, J. I., Politi, P., Solmi, M., … Fusar-Poli, P. (2021b). Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine, 36, 100909. https://doi.org/10.1016/j.eclinm.2021.100909
   PubMedGoogle Scholar
• Salazar de Pablo, G., Catalan, A., & Fusar-Poli, P. (2020a). Clinical validity of DSM-5 attenuated psychosis syndrome: advances in diagnosis, prognosis, and treatment. JAMA Psychiatry, 77(3), 311–320. https://doi.org/10.1001/jamapsychiatry.2019.3561
   PubMed Web of Science ®Google Scholar
• Salazar de Pablo, G., Estradé, A., Cutroni, M., Andlauer, O., & Fusar-Poli, P. (2021c). Establishing a clinical service to prevent psychosis: What, how and when? Systematic review. Translational Psychiatry, 11(1), 43. https://doi.org/10.1038/s41398-020-01165-x
   PubMed Web of Science ®Google Scholar
• Salazar de Pablo, G., Radua, J., Pereira, J., Bonoldi, I., Arienti, V., Besana, F., Soardo, L., Cabras, A., Fortea, L., Catalan, A., Vaquerizo-Serrano, J., Coronelli, F., Kaur, S., Da Silva, J., Shin, J. I., Solmi, M., Brondino, N., Politi, P., McGuire, P., & Fusar-Poli, P. (2021a). Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis. JAMA Psychiatry, 78(9), 970–978. https://doi.org/10.1001/jamapsychiatry.2021.0830
   PubMed Web of Science ®Google Scholar
• Salazar de Pablo, G., Soardo, L., Cabras, A., Pereira, J., Kaur, S., Besana, F., Arienti, V., Coronelli, F., Shin, J. I., Solmi, M., Petros, N., Carvalho, A. F., McGuire, P., & Fusar-Poli, P. (2022). Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis. Epidemiology and Psychiatric Sciences, 31, e9. https://doi.org/10.1017/S2045796021000639
   PubMed Web of Science ®Google Scholar
• Schneider, M., Armando, M., Pontillo, M., Vicari, S., Debbané, M., Schultze-Lutter, F., & Eliez, S. (2016). Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome. World Psychiatry : official Journal of the World Psychiatric Association (WPA), 15(3), 259–265.
   PubMed Web of Science ®Google Scholar
• Schneider, M., Debbané, M., Bassett, A. S., Chow, E. W. C., Fung, W. L. A., van den Bree, M., Owen, M., Murphy, K. C., Niarchou, M., Kates, W. R., Antshel, K. M., Fremont, W., McDonald-McGinn, D. M., Gur, R. E., Zackai, E. H., Vorstman, J., Duijff, S. N., Klaassen, P. W. J., Swillen, A., … Eliez, S., International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. (2014). Psychiatric disorders from childhood to adulthood in 22q11.2 Deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. The American Journal of Psychiatry, 171(6), 627–639. https://doi.org/10.1176/appi.ajp.2013.13070864
   PubMed Web of Science ®Google Scholar
• Solmi, M., Radua, J., Olivola, M., Croce, E., Soardo, L., Salazar de Pablo, G., Il Shin, J., Kirkbride, J. B., Jones, P., Kim, J. H., Kim, J. Y., Carvalho, A. F., Seeman, M. V., Correll, C. U., & Fusar-Poli, P. (2022). Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Molecular Psychiatry, 27(1), 281–295. https://doi.org/10.1038/s41380-021-01161-7
   PubMed Web of Science ®Google Scholar
• Solot, C. B., Gerdes, M., Kirschner, R. E., McDonald-McGinn, D. M., Moss, E., Woodin, M., Aleman, D., Zackai, E. H., & Wang, P. P. (2001). Communication issues in 22q11.2 deletion syndrome: children at risk. Genetics in Medicine : official Journal of the American College of Medical Genetics, 3(1), 67–71. https://doi.org/10.1097/00125817-200101000-00015
   PubMed Web of Science ®Google Scholar
• Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., & Thacker, S. B. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283(15), 2008–2012. https://doi.org/10.1001/jama.283.15.2008
   PubMed Web of Science ®Google Scholar
• Sun, D., Ching, C. R. K., Lin, A., Forsyth, J. K., Kushan, L., Vajdi, A., Jalbrzikowski, M., Hansen, L., Villalon-Reina, J. E., Qu, X., Jonas, R. K., van Amelsvoort, T., Bakker, G., Kates, W. R., Antshel, K. M., Fremont, W., Campbell, L. E., McCabe, K. L., Daly, E., … Bearden, C. E. (2020). Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. Molecular Psychiatry, 25(8), 1822–1834. https://doi.org/10.1038/s41380-018-0078-5
   PubMed Web of Science ®Google Scholar
• Swillen, A., Feys, H., Adriaens, T., Nelissen, L., Mertens, L., Gewillig, M., Devriendt, K., & Fryns, J.-P. (2005). Early motor development in young children with 22q.11 deletion syndrome and a conotruncal heart defect. Developmental Medicine & Child Neurology, 47(12), 797–802. https://doi.org/10.1017/S0012162205001696
   PubMed Web of Science ®Google Scholar
• Swillen, A., Moss, E., & Duijff, S. (2018). Neurodevelopmental outcome in 22q11.2 deletion syndrome and management. American Journal of Medical Genetics. Part A, 176(10), 2160–2166. https://doi.org/10.1002/ajmg.a.38709
   PubMed Web of Science ®Google Scholar
• Swillen, A., Vogels, A., Devriendt, K., & Fryns, J. P. (2000). Chromosome 22q11 deletion syndrome: Update and review of the clinical features, cognitive-behavioral spectrum, and psychiatric complications. American Journal of Medical Genetics, 97(2), 128–135. https://doi.org/10.1002/1096-8628(200022)97:2 < 128::AID-AJMG4 > 3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Tang, S. X., Yi, J. J., Moore, T. M., Calkins, M. E., Kohler, C. G., Whinna, D. A., Souders, M. C., Zackai, E. H., McDonald-McGinn, D. M., Emanuel, B. S., Bilker, W. B., Gur, R. C., & Gur, R. E. (2014). Subthreshold psychotic symptoms in 22q11.2 deletion syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 53(9), 991–1000.e2. https://doi.org/10.1016/j.jaac.2014.05.009
   PubMed Web of Science ®Google Scholar
• Thompson, C. A., Karelis, J., Middleton, F. A., Gentile, K., Coman, I. L., Radoeva, P. D., Mehta, R., Fremont, W. P., Antshel, K. M., Faraone, S. V., & Kates, W. R. (2017). Associations between neurodevelopmental genes, neuroanatomy, and ultra high risk symptoms of psychosis in 22q11.2 deletion syndrome. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International Society of Psychiatric Genetics, 174(3), 295–314. https://doi.org/10.1002/ajmg.b.32515
   PubMed Web of Science ®Google Scholar
• van Drimmelen-Krabbe, J., Bertelsen, A., & Pull, C. (2001). Conversion Tables for ICD-10 and DSM-IV, in Contemporary Psychiatry: Volume 1 Foundations of Psychiatry, Volume 2 Psychiatry in Special Situations, Volume 3 Specific Psychiatric Disorders (F. Henn, Ed.) Springer Berlin Heidelberg. p. 451–478.
   Google Scholar
• Villalon-Reina, J. E. (2020). Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study. Molecular Psychiatry, 25(11), 2818–2831. https://doi.org/10.1038/s41380-019-0450-0
   PubMed Web of Science ®Google Scholar
• Vingerhoets, C., van Oudenaren, M. J., Bloemen, O. J., Boot, E., van Duin, E. D., Evers, L. J., Fiksinski, A. M., Breetvelt, E. J., Palmer, L. D., Vergaelen, E., Vogels, A., Meijer, C., Booij, J., de Haan, L., Swillen, A., Vorstman, J. A., Bassett, A. S., & van Amelsvoort, T. A., Genetic Risk and Outcome of Psychosis (GROUP) investigators. (2019). Low prevalence of substance use in people with 22q11.2 deletion syndrome. British Journal of Psychiatry, 215(5), 661–667. https://doi.org/10.1192/bjp.2018.258
   PubMed Web of Science ®Google Scholar
• Vorstman, J. A. S., Breetvelt, E. J., Duijff, S. N., Eliez, S., Schneider, M., Jalbrzikowski, M., Armando, M., Vicari, S., Shashi, V., Hooper, S. R., Chow, E. W. C., Fung, W. L. A., Butcher, N. J., Young, D. A., McDonald-McGinn, D. M., Vogels, A., van Amelsvoort, T., Gothelf, D., Weinberger, R., … Bassett, A. S., International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome (2015). Cognitive decline preceding the onset of psychosis in patients With 22q11.2 deletion syndrome. Jama Psychiatry, 72(4), 377–385. https://doi.org/10.1001/jamapsychiatry.2014.2671
   PubMed Web of Science ®Google Scholar
• Weisman, O., Guri, Y., Gur, R. E., McDonald-McGinn, D. M., Calkins, M. E., Tang, S. X., Emanuel, B., Zackai, E. H., Eliez, S., Schneider, M., Schaer, M., Kates, W. R., Antshel, K. M., Fremont, W., Shashi, V., Hooper, S. R., Armando, M., Vicari, S., Pontillo, M., … Gothelf, D, International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome (2017). Subthreshold psychosis in 22q11.2 deletion syndrome: multisite naturalistic study. Schizophrenia Bulletin, 43(5), 1079–1089. https://doi.org/10.1093/schbul/sbx005
   PubMed Web of Science ®Google Scholar
• Wells, G. (2014). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Zinkstok, J. R., Boot, E., Bassett, A. S., Hiroi, N., Butcher, N. J., Vingerhoets, C., Vorstman, J. A. S., & van Amelsvoort, T. A. M. J. (2019). Neurobiological perspective of 22q11.2 deletion syndrome. The Lancet. Psychiatry, 6(11), 951–960. https://doi.org/10.1016/S2215-0366(19)30076-8
   PubMed Web of Science ®Google Scholar